Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription 07.11.2022 3 BMC Urol 2 Br J Cancer 1 Cancer 1 Cancer Res 2 Clin Cancer Res 1 Eur Urol 1 Int J Urol 3 J Magn Reson Imaging 4 J Nucl Med 1 J Urol 2 Lancet Oncol 2 Nat Rev Urol 1 PLoS One 4 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Urol

1. ZHU S, Hu X, Fan Y
   Association of triglyceride levels and prostate cancer: a Mendelian randomization study.
   BMC Urol. 2022;22:167.
   PubMed         Abstract available
   
   
2. CUONG NC, Vien NT, Thien NM, Hai PT, et al
   Hospital-based prostate cancer screening in vietnamese men with lower urinary tract symptoms: a classification and regression tree model.
   BMC Urol. 2022;22:166.
   PubMed         Abstract available
   
   
3. KIM DG, Yoo JW, Koo KC, Chung BH, et al
   Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer.
   BMC Urol. 2022;22:164.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
   Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
   Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
   PubMed         Abstract available
   
   
5. LAN T, Park Y, Colditz GA, Liu J, et al
   Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
   Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02035.
   PubMed         Abstract available
   
   

   
   Cancer

6. 
   MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis.
   Cancer. 2022;128:3906.
   PubMed        
   
   

   
   Cancer Res

7. WU A, Attard G
   Accidentals of the DNA Symphony.
   Cancer Res. 2022;82:3880-3881.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

8. MATSUBARA N, de Bono J, Olmos D, Procopio G, et al
   Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
   Clin Cancer Res. 2022 Nov 1. pii: 710156. doi: 10.1158/1078-0432.CCR-21-3577.
   PubMed         Abstract available
   
   
9. QUINN Z, Leiby B, Sonpavde G, Choudhury AD, et al
   Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.
   Clin Cancer Res. 2022 Nov 2. pii: 710187. doi: 10.1158/1078-0432.CCR-22-2526.
   PubMed         Abstract available
   
   

   
   Eur Urol

10. FERGUSON EL, Kaouk JH
    Reply to Minxiong Hu and Liefu Ye's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Oct 25. pii: S0302-2838(22)02722.
    PubMed        
    
    

    
    Int J Urol

11. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
    Int J Urol. 2022 Oct 31. doi: 10.1111/iju.15090.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

12. CLEMMENSEN A, Loft M, Kjaer A, Andersen TL, et al
    Editorial for "Application of 3D Multi-Echo Balanced Steady State Free Precession and Hyperpolarized [1-(13) C] Pyruvate to Quantify Prostate Cancer Metabolism".
    J Magn Reson Imaging. 2022 Nov 3. doi: 10.1002/jmri.28483.
    PubMed        
    
    
13. LI X, Li C, Chen M
    Patients With "Gray Zone" PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer.
    J Magn Reson Imaging. 2022 Nov 3. doi: 10.1002/jmri.28505.
    PubMed         Abstract available
    
    
14. CHOWDHURY R, Mueller CA, Smith L, Gong F, et al
    Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-(13) C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade.
    J Magn Reson Imaging. 2022 Oct 31. doi: 10.1002/jmri.28467.
    PubMed         Abstract available
    
    

    
    J Nucl Med

15. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
    PubMed         Abstract available
    
    
16. WANG G, Zang J, Jiang Y, Liu Q, et al
    A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264857. doi: 10.2967/jnumed.122.264857.
    PubMed         Abstract available
    
    
17. JADVAR H, Abreu AL, Ballas LK, Quinn DI, et al
    Oligometastatic Prostate Cancer: Current Status and Future Challenges.
    J Nucl Med. 2022;63:1628-1635.
    PubMed         Abstract available
    
    
18. BELLAVIA MC, Patel RB, Anderson CJ
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
    PubMed         Abstract available
    
    

    
    J Urol

19. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
    Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
    J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

20. SINGH K, Mandal S, Nayak P, Das M, et al
    Rezvilutamide for metastatic hormone-sensitive prostate cancer.
    Lancet Oncol. 2022;23:e490.
    PubMed        
    
    
21. YE D, Gu W, Li J
    Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply.
    Lancet Oncol. 2022;23:e491.
    PubMed        
    
    

    
    Nat Rev Urol

22. MASONE MC
    WGC in patients with localized prostate cancer.
    Nat Rev Urol. 2022 Oct 31. pii: 10.1038/s41585-022-00673.
    PubMed        
    
    
23. ALGHAZO O, O'Callaghan M
    PSMA-PET to detect prostate cancer recurrence after radiotherapy.
    Nat Rev Urol. 2022 Oct 31. pii: 10.1038/s41585-022-00672.
    PubMed        
    
    

    
    PLoS One

24. BARBIER MC, Tomonaga Y, Menges D, Yebyo HG, et al
    Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    PLoS One. 2022;17:e0277282.
    PubMed         Abstract available
    
    

    
    Prostate

25. LEE EE, Singh T, Hu C, Han M, et al
    The impact of salvage radiotherapy initiation at PSA
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24452.
    PubMed         Abstract available
    
    
26. OISHI T, Hatakeyama S, Tabata R, Fujimori D, et al
    Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24453.
    PubMed         Abstract available
    
    
27. AMARO GM, da Silva ADT, Tamarindo GH, Lamas CA, et al
    Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Prostate. 2022;82:1491-1504.
    PubMed         Abstract available
    
    
28. DENMEADE S, Lim SJ, Isaaccson Velho P, Wang H, et al
    PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Prostate. 2022;82:1529-1536.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: